Feature Combination immunotherapy: the emerging treatment that removes cancer’s “cloak of invisibility”

Last year’s Nobel prize in physiology or medicine went to James P Allison and Tasuku Honjo for their work on cancer immunotherapy. Some doctors think that the emerging use of these treatments in combination, and with other treatments such as chemotherapy and radiotherapy, will lead to a step change in survival rates, particularly in cancers that are hard to treat.

Ten years ago patients with a diagnosis such as melanoma or lung cancer, which don’t respond well to traditional methods such as chemotherapy and radiotherapy, received a grim prognosis. Immunotherapy has changed this for some patients. For example, a randomised trial of 272 patients with advanced, previously treated squamous cell non-small cell lung cancer (NSCLC) found that the immunotherapy nivolumab (Opdivo, Bristol-Myers Squibb) increased one year survival to 42%, compared with 24% with chemotherapy (docetaxel).1

Avacta Group Plc (LON:AVCT) principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Innovations in neutralising therapies

Coronaviruses are a large family of viruses that cause illnesses like the common cold, but can also cause more severe diseases such as Middle East Respiratory Syndrome (MERS) and Sever Acute Respiratory Syndrome (SARS). The novel

Avacta Group Plc

Biopharma update on the novel Coronavirus – July

Testing Therapies, Antivirals and Vaccines Avacta Group has partnered with the U.K. government’s CONDOR program to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry laboratory assay developed with Adeptrix. Adeptrix’s novel BAMS platform uses

Avacta Group Plc

Biopharma update on the novel Coronavirus

Testing Therapies, Antivirals and Vaccines Avacta Group entered into a collaboration with Integumen plc to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in wastewater, to provide a real-time alert

Avacta Group Plc

Commercial potential for waste water Covid-19 detection

Life sciences business Avacta Group has become the second Yorkshire firm to partner with Integumen on Covid-19 detection systems for wastewater. The Wetherby-based listed firm has entered into a collaboration agreement with Integumen to evaluate its

Avacta Group Plc

preCISION and Affimer based cancer therapies

In this interview, Alastair Smith discusses our development of a rapid antigen test for SARS-Cov-2 and the progress of our preCISIONTM and Affimer® based cancer therapies. Watch below.  Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology

Avacta Group Plc

Avacta Group wins Small Cap award

Avacta Group has won Technology Company of the Year at the Small Cap 2020 Awards. Over 200 attendees, all supporters of the small cap community congregated online at the (optional) black tie event. Companies and advisors

Avacta Group Plc

How diagnostic test performance is measured

In this video, Avacta’s Chief Executive Officer Alastair Smith explains how diagnostic test performance is measured. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United

Avacta Group Plc

The Quest for a Cure

In 2003, the outbreak of severe acute respiratory syndrome (SARS) became the first pandemic of the 21st century and exemplified the rapid rate at which a virus can spread internationally. Originating in China, SARS quickly spread